# Multicenter Retrospective Review of Ketamine Use in Pediatric Intensive Care Units (Ketamine-PICU Study)

**Authors:** Christine M. Groth, Christopher A. Droege, Preeyaporn Sarangarm, Michaelia D. Cucci, Kyle A. Gustafson, Kathryn A. Connor, Kimberly Kaukeinen, Nicole M. Acquisto, Sai Ho J. Chui, Deepali Dixit, Alexander H. Flannery, Nina E. Glass, Helen Horng, Mojdeh S. Heavner, Justin Kinney, William J. Peppard, Andrea Sikora, Brian L. Erstad

PMC · DOI: 10.1155/2024/6626899 · Critical Care Research and Practice · 2024-07-27

## TL;DR

This study examines how ketamine infusions affect pain management and medication use in critically ill children, finding initial benefits but calling for more research.

## Contribution

The study provides new insights into ketamine's impact on pain scores and analgesic use in pediatric intensive care.

## Key findings

- Ketamine improved time in goal pain score range compared to before infusion.
- Morphine use decreased significantly in the first 24 hours of ketamine infusion.
- Common adverse effects included tachycardia and hypotension.

## Abstract

Describe continuous infusion (CI) ketamine practices in pediatric intensive care units (PICUs) and evaluate its effect on pain/sedation scores, exposure to analgesics/sedatives, and adverse effects (AEs).

Multicenter, retrospective, observational study in children <18 years who received CI ketamine between 2014 and 2017. Time spent in goal pain/sedation score range and daily cumulative doses of analgesics/sedatives were compared from the 24 hours (H) prior to CI ketamine to the first 24H and 25−48H of the CI. Adverse effects were collected over the first 7 days of CI ketamine.

Twenty-four patients from 4 PICUs were included; median (IQR) age 7 (1-13.25) years, 54% female (n = 13), 92% intubated (n = 22), 25% on CI vasopressors (n = 6), and 33% on CI paralytics (n = 8). Ketamine indications were analgesia/sedation (n = 21, 87.5%) and status epilepticus (n = 3, 12.5%). Median starting dose was 0.5 (0.48–0.70) mg/kg/hr and continued for a median of 2.4 (1.3–4.4) days. There was a significant difference in mean proportion of time spent within goal pain score range (24H prior: 74% ± 14%, 0–24H: 85% ± 10%, and 25−48H: 72% ± 20%; p=0.014). A significant reduction in median morphine milligram equivalents (MME) was seen (24H prior: 58 (8–195) mg vs. 0–24H: 4 (0–69) mg and p=0.01), but this was not sustained (25−48H: 24 (2–246) mg and p=0.29). Common AEs were tachycardia (63%), hypotension (54%), secretions/suctioning (29%), and emergence reactions (13%).

Ketamine CI improved time in goal pain score range and significantly reduced MME, but this was not sustained. Larger prospective studies are needed in the pediatric population.

## Linked entities

- **Chemicals:** ketamine (PubChem CID 3821), morphine (PubChem CID 5288826)

## Full-text entities

- **Diseases:** pain (MESH:D010146), paralytics (MESH:D000092164), hypotension (MESH:D007022), tachycardia (MESH:D013610), status epilepticus (MESH:D013226)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11300064/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC11300064/full.md

---
Source: https://tomesphere.com/paper/PMC11300064